Kielce

• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Ended recruitment
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S … Ended recruitment
  2022-501622-37-00 5 2024-01-16 Multiple Sclerosis
• A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD … Ended recruitment
  2022-501343-33-00 5 2023-10-18 Biochemically recurrent prostate cancer
• Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma Ended recruitment
  2023-503652-27-00 5 2023-10-06 Melanoma
• A Study to Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophospha … Ended recruitment
  2023-504028-24-00 5 2023-09-22 Large B-Cell Lymphoma
• A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS) Ended recruitment
  2022-502700-78-00 5 2023-09-01 Alopecia areata (AA)
• A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas … Ended recruitment
  2023-503444-13-00 5 2023-03-29 Relapsed/refractory multiple myeloma
• A Study of Giredestrant in Patients with Grade 1 Endometrial Cancer Ended recruitment
  2023-504091-23-00 4 2023-03-14 Grade 1 Endometrial Cancer
• A Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cut … Ended recruitment
  2023-505634-94-00 10 2023-02-02 Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythe
• A Study of Dato-DXd in Combination With Durvalumab and Carboplatin for First-line Treatment of Advanced NSCLC Without Actionable Genomic Alt … Ended recruitment
  2023-505993-14-00 5 2023-01-05 Non-Small Cell Lung Cancer (NSCLC)
• This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in … Ended recruitment
  2023-505628-67-00 5 2022-10-28 Relapsed and Refractory Follicular Lymphoma
• A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin … Ended recruitment
  2023-503467-41-00 5 2022-10-12 Relapsed or Refractory Multiple Myeloma
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat … Ended recruitment
  2023-509345-12-00 5 2022-06-22 Multiple Sclerosis
• Phase 3 study of pembrolizumab vs chemotherapy in dMMR advanced or recurrent endometrial carcinoma Ended recruitment
  2023-506361-56-00 5 2022-04-01 Endometrial cancer
• Clinical trial conducted to evaluate the effectiveness of a combination of drugs called venetoclax and rituximab adapted to the state of min … Ended recruitment
  2024-518494-34-00 4 2022-02-24 Chronic lymphocytic leukemia
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• Pembrolizumab/placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer. Ended recruitment
  2023-506177-35-00 11 2021-10-23 Ovarian, fallopian tube, or primary peritoneal carcinoma.
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa … Ended recruitment
  2023-503441-55-00 4 2021-10-14 Relapsed/Refractory Multiple Myeloma
• AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia - A randomized phas … Ended recruitment
  2024-517253-27-00 5 2021-07-01 Acute lymphoblastic leukemia
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis Ended recruitment
  2022-502618-95-00 5 2020-11-24 Relapsing multiple sclerosis (RMS)
• Apalutamide, Radiotherapy and LHRH Agonist in High-Risk Hormone-Sensitive Prostate Cancer Patients Assessed by PSMA-PET Ended recruitment
  2023-505852-23-00 5 2020-11-12 High risk recurrent prostate cancer previously treated with radical pr
• RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients … Ended recruitment
  2023-505830-89-00 6 2020-08-05 metastatic castrate resistant prostate cancer (mCRPC)
• Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiothera … Ended recruitment
  2022-501973-37-00 5 2020-01-30 Endometrial cancer
• Research study to comparison the effectivenes of combination of drugs called lenalidomide, carfilzomib, dexamethasone with combination of dr … Ended recruitment
  2024-518473-34-00 5 2019-11-20 Multiple Myeloma

Showing 97–120 of 173 trials